[1]况福连,刘明盛.白细胞介素-11联合生血宝治疗恶性肿瘤化疗后血小板减少的疗效观察[J].医学信息,2024,37(24):111-113,121.[doi:10.3969/j.issn.1006-1959.2024.24.030]
　KUANG Fulian,LIU Mingsheng.Observation on the Curative Effect of Interleukin-11 Combined with Shengxuebao in the Treatment of Thrombocytopenia After Chemotherapy for Malignant Tumors[J].Journal of Medical Information,2024,37(24):111-113,121.[doi:10.3969/j.issn.1006-1959.2024.24.030]
点击复制

白细胞介素-11联合生血宝治疗恶性肿瘤化疗后血小板减少的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年24期
页码:
111-113,121
栏目:
中医中药
出版日期:
2024-12-15

文章信息/Info

Title:
Observation on the Curative Effect of Interleukin-11 Combined with Shengxuebao in the Treatment of Thrombocytopenia After Chemotherapy for Malignant Tumors
文章编号:
1006-1959（2024）24-0111-04
作者:
况福连; 刘明盛
宜丰县人民医院内六科，江西 宜丰 336300
Author(s):
KUANG Fulian; LIU Mingsheng
The Sixth Department of Internal Medicine,Yifeng County People’s Hospital,Yifeng 336300,Jiangxi,China
关键词:
白细胞介素-11; 生血宝; 恶性肿瘤; 化疗; 血小板减少
Keywords:
Interleukin-11; Shengxuebao; Malignant tumor; Chemotherapy; Thrombocytopenia
分类号:
R558+.2
DOI:
10.3969/j.issn.1006-1959.2024.24.030
摘要:
目的 探讨白细胞介素-11联合生血宝治疗恶性肿瘤化疗后血小板减少的疗效。方法 选取2019年1月-2023年10月宜丰县人民医院收治的60例恶性肿瘤患者为研究对象，按照随机数字表法分为研究组和对照组，各30例。对照组患者采用白细胞介素-11治疗，研究组患者采用白细胞介素-11联合生血宝治疗。比较两组临床疗效、血小板减少症发生率、血小板计数（PC）及血小板计数变化情况。结果 研究组治疗总有效率高于对照组（P＜0.05）；研究组血小板减少症发生率低于对照组（P＜0.05）；两组治疗后PC水平高于治疗前，且研究组PC水平高于对照组（P＜0.05）。研究组血小板计数＜50×109/L持续时间、恢复至70×109/L所需时间、恢复至100×109/L所需时间均短于对照组（P＜0.05）。结论 白细胞介素-11联合生血宝治疗恶性肿瘤化疗后血小板减少的效果确切，能够更有效预防恶性肿瘤化疗后血小板减少症，缩短患者血小板计数恢复正常时间。
Abstract:
Objective To investigate the efficacy of interleukin-11 combined with Shengxuebao in the treatment of thrombocytopenia after chemotherapy for malignant tumors.Methods A total of 60 patients with malignant tumors admitted to Yifeng County People’s Hospital from January 2019 to October 2023 were selected as the research objects. According to the random number table method, they were divided into study group and control group, with 30 patients in each group. The control group was treated with interleukin-11, and the study group was treated with interleukin-11 combined with Shengxuebao. The clinical efficacy, incidence of thrombocytopenia, platelet count (PC) and platelet count changes were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group (P<0.05). The incidence of thrombocytopenia in the study group was lower than that in the control group (P<0.05). The PC level of the two groups after treatment was higher than that before treatment, and the PC level of the study group was higher than that of the control group (P<0.05). The duration of platelet count <50×109/L, the time required to recover to 70×109/L, and the time required to recover to 100×109/L in the study group were shorter than those in the control group (P<0.05).Conclusion Interleukin-11 combined with Shengxuebao is effective in the treatment of thrombocytopenia after chemotherapy for malignant tumors. It can more effectively prevent thrombocytopenia after chemotherapy for malignant tumors, and shorten the time for platelet count to return to normal.

参考文献/References:

[1]唐春娟,侯蕊,李禹兵.重组人白细胞介素-11预防急性白血病化疗后血小板减少疗效观察[J].海南医学,2019,30(2):169-171.[2]吴玉玲,汪琼,余超,等.激素联合重组人白细胞介素-11治疗重症原发免疫性血小板减少症的近期疗效[J].海军医学杂志,2019,40(4):324-326,346.[3]刘自建,骆泉湘,刘芝兰.重组人白细胞介素-11治疗实体瘤化疗所致血小板减少的疗效观察[J].中国肿瘤临床与康复,2018,25(4):439-442.[4]王宗平.糖皮质激素联合重组人白细胞介素-11在原发免疫性血小板减少症中的应用[J].中国药物与临床,2020,20(6):923-924.[5]毛延涛,张耀.注射用重组人白细胞介素-11致急性心力衰竭1例[J].肿瘤药学,2021,11(1):126-128.[6]韩瑛,张晶,李淑敏,等.重组人血小板生成素预防卵巢癌化疗相关血小板减少症的疗效和安全性[J].现代肿瘤医学,2022,30(10):1855-1859.[7]孙新建,马海洋,李文军,等.rhTPO与rhIL-11治疗严重创伤所致重度血小板减少的疗效研究[J].检验医学与临床,2020,17(5):671-674.[8]于艺冰,张琳,孔艳,等.rhIL-11联合利妥昔单克隆抗体对免疫性血小板减少症患者NK细胞、色氨酸代谢的影响[J].分子诊断与治疗杂志,2023,15(7):1261-1264,1269.[9]韩晶,门鹏,刘维,等.重组人血小板生成素治疗原发性免疫性和肿瘤化疗后血小板减少症的快速卫生技术评估[J].中国新药杂志,2020,29(5):589-594.[10]吴林,张光彩,周晓晖,等.温针灸对高血压脑出血恢复期气虚血瘀患者S100B、MMP-9、Hcy及炎性因子水平的影响[J].上海针灸杂志,2021,40(8):907-912. [11]孙少勤.重组人血小板生成素治疗血液肿瘤化疗所致血小板减少症疗效[J].临床输血与检验,2018,20(6):632-635.[12]封蔚莹,罗洪强,李丹,等.rhIL-11联合标准剂量地塞米松治疗新诊断PITP患者的临床评价[J].重庆医学,2020,49(9):1455-1459.[13]王文焕,李小燕.Notch-芳香烃受体-白细胞介素-22通路在急性特发性血小板减少性紫癜中的作用[J].免疫学杂志,2020,36(3):241-247.[14]周志刚,谢云,冯铁男,等.血小板计数短期动态变化对ICU脓毒症患者预后的临床预测价值：一项成人的回顾性队列研究[J].中华危重病急救医学,2020,32(3):301-306.[15]高雅婷,张永军.基于Caspase途径探讨花生红衣对化疗后血小板减少症小鼠的影响[J].新中医,2020,52(19):1-3.[16]乌日罕,苏乌云,邢舴,等.rhTPO治疗XELOX/SOX方案化疗所致血小板减少症的疗效研究[J].重庆医学,2020,49(24):4070-4074.[17]陈莉,林澜澜,林珅,等.rhTPO与IL-11治疗化疗相关血小板减少症的成本效果分析[J].中国现代应用药学,2019,36(19):2445-2449.[18]钟欢,叶伟.阿伐曲泊帕治疗肝硬化和原发性肝癌患者血小板减少症疗效分析[J].实用肝脏病杂志,2023,26(3):440-442.[19]林希丹.穴位埋线对中风偏瘫患者足底压力及下肢运动功能的影响[D].福州:福建中医药大学,2019.[20]常虹,潘竹林,许惠利.重组人血小板生成素治疗非霍奇金淋巴瘤化疗后血小板减少的临床分析[J].血栓与止血学,2020,26(1):7-9.

更新日期/Last Update: 1900-01-01